Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Translational Oncology"
DOI: 10.1016/j.tranon.2020.100920
Abstract: Highlights • The glutamine utilization of KRAS-mutant NSCLC is higher than that of KRAS wild-type.• Targeted GLS1 and MEK inhibition enhance antitumor activity in vitro and in vivo.• The therapeutic response can be well identified… read more here.
Keywords: mutant nsclc; inhibition; inhibition glutamine; gls1 mek ... See more keywords
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-18-1542
Abstract: Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described. Experimental Design: Using cohorts from… read more here.
Keywords: egfr mutant; mutant nsclc; continuation; resistance ... See more keywords
Abstract 4650: High intratumoral levels of Notch3 increase tumorigenesis and promote an immunosuppressive TME in EGFR-mutant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4650
Abstract: Activating mutations in the Epidermal Growth Factor Receptor (EGFR) are one of the most common driver mutations in non-small cell lung cancer (NSCLC). They are present in the tumors of ~15% of Caucasian patients and… read more here.
Keywords: increase; egfr mutant; levels notch3; mutant nsclc ... See more keywords
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps9110
Abstract: TPS9110Background: While outcomes for patients with EGFR-mutant NSCLC have significantly improved with the use of EGFR tyrosine kinase inhibitors, there remain limited treatment options for many pa... read more here.
Keywords: egfr mutant; mutant nsclc; anti her3; study anti ... See more keywords
EGFR first- and second-generation TKIs—there is still place for them in EGFR -mutant NSCLC patients
Sign Up to like & getrecommendations! Published in 2018 at "Translational cancer research"
DOI: 10.21037/24920
Abstract: Identification of epidermal growth factor receptor (EGFR) as a molecular target has radically changed the treatment of metastatic non-small cell lung cancer (NSCLC) from standard chemotherapy to personalized, targeted therapy. First-, second- and third-generation EGFR… read more here.
Keywords: egfr mutant; mutant nsclc; nsclc patients; first second ... See more keywords
Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.
Sign Up to like & getrecommendations! Published in 2018 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2018.03.20
Abstract: KRAS mutant NSCLC cells require active nuclear export of Iκβα (also known as NFKBIA), a negative regulatory protein of NF-κB signaling, for maintaining survival signaling (1-3). Nuclear export receptor XPO1 correlates with KRAS mutation status. read more here.
Keywords: inhibition mek; mutant nsclc; canonical kras; kras mutant ... See more keywords
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
Sign Up to like & getrecommendations! Published in 2023 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s407301
Abstract: Purpose Although serum neutrophil-to-lymphocyte ratio (NLR) is correlated with the outcome of various cancer types, its role in treatment-naïve, advanced, epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with osimertinib remains… read more here.
Keywords: nsclc patients; role; egfr mutant; first line ... See more keywords
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16040553
Abstract: KRASG12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRASG12C inhibitors, sotorasib and adagrasib, have been an… read more here.
Keywords: cell; krasg12c inhibitors; krasg12c; mutant nsclc ... See more keywords